BBP vs WDNA

BBPAVirtus Biotech ETF

WDNACWisdomTree BioRevolution Fund

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

WDNA Most biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

WDNA The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.

Why people hold it

• BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
• 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
• Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
• One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

• WDNA Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
• The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
• Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com

Worth knowing

• BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
• Income is not the point here. The fund has not been paying distributions, so the return story is price.
• An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

• WDNA A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
• For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
• The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com

Full BBP profile⁠

Full WDNA profile⁠